Chrome Extension
WeChat Mini Program
Use on ChatGLM

Detection of EGFR Mutations in Cfdna and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients

Frontiers in oncology(2020)SCI 3区

Vortex Biosci Inc | Univ Calif Los Angeles | Stanford Univ

Cited 43|Views67
Abstract
Lung cancer is the leading cause of cancer-related mortality worldwide. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapies, based on the evaluation of EGFR mutations, have shown dramatic clinical benefits. EGFR mutation assays are mainly performed on tumor biopsies, which carry risks, are not always successful and give results relevant to the timepoint of the assay. To detect secondary EGFR mutations, which cause resistance to 1st and 2nd generation TKIs and lead to the administration of a 3rd generation drug, effective and non-invasive monitoring of EGFR mutation status is needed. Liquid biopsy analytes, such as circulating tumor cells (CTCs) and circulating tumor DNA (cfDNA), allow such monitoring over the course of the therapy. The aim of this study was to develop and optimize a workflow for the evaluation of cfDNA and CTCs in NSCLC patients all from one blood sample. Using Vortex technology and EntroGen ctEGFR assay, EGFR mutations were identified at 0.5 ng of DNA (∼83 cells), with a sensitivity ranging from 0.1 to 2.0% for a total DNA varying from 25 ng (∼4 CTCs among 4000 white blood cells, WBCs) to 1 ng (∼4 CTCs among 200 WBCs). The processing of plasma-depleted-blood provided comparable capture recovery as whole blood, confirming the possibility of a multimodality liquid biopsy analysis (cfDNA and CTC DNA) from a single tube of blood. Different anticoagulants were evaluated and compared in terms of respective performance. Blood samples from 24 NSCLC patients and 6 age-matched healthy donors were analyzed with this combined workflow to minimize blood volume needed and sample-to-sample bias, and the EGFR mutation profile detected from CTCs and cfDNA was compared to matched tumor tissues. Despite the limited size of the patient cohort, results from this non-invasive EGFR mutation analysis are encouraging and this combined workflow represents a valuable means for informing therapy selection and for monitoring treatment of patients with NSCLC.
More
Translated text
Key words
Vortex technology,circulating tumor cell,total liquid biopsy,epidermal grow factor receptor,EGFR mutation analysis,Non-small cell carcinoma,circulating tumor biomarkers,circulating free DNA (cfDNA)
PDF
Bibtex
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
  • Pretraining has recently greatly promoted the development of natural language processing (NLP)
  • We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
  • We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
  • The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
  • Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Try using models to generate summary,it takes about 60s
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Related Papers

Ion Transporting Proteins and Cancer: Progress and Perspectives

Reviews of physiology, biochemistry and pharmacology 2021

被引用3

Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper

要点】:本研究旨在开发并优化从一份血液样本中评估非小细胞肺癌(NSCLC)患者循环肿瘤细胞(CTCs)和循环肿瘤DNA(cfDNA)的工作流程,以实现对EGFR突变的无创监测,并与肿瘤组织进行对比。

方法】:研究采用Vortex技术和EntroGen ctEGFR检测方法,对cfDNA和CTCs进行EGFR突变检测,优化了从单个血液样本中同时获取cfDNA和CTCs的流程。

实验】:24名NSCLC患者和6名年龄匹配的健康捐赠者的血液样本使用该联合工作流程进行分析,以最小化所需血量和样本间偏差,实验结果将CTCs和cfDNA中检测到的EGFR突变特征与相应的肿瘤组织进行了比较。